Trial · NCT04982939
Peri-operative Sintilimab in Combination With SOX in Locally Advanced Gastric Cancer
NCT04982939, Phase 2, Unknown, Tianjin Medical University Cancer Institute and Hospital
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Peri-operative Sintilimab in Combination With SOX in Locally Advanced Gastric Cancer. Trials, record NCT04982939. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04982939
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Peri-operative Sintilimab in Combination With SOX in Locally Advanced Gastric Cancer
- NCT number
- NCT04982939
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 210 participants, estimated
- Lead sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Conditions
- Gastric Cancer, Perioperative, Sintilimab
- Interventions
- Sintilimab, S-1, Oxaliplatin
- First posted
- 2021-07-29
- Last updated
- 2021-08-31
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Pathological complete response (pCR) rate | up to 8 weeks after surgery | Pathological complete response (pCR) rate is defined as the proportion of participants whose tumor in the stomach and lymph node completely disappeared, as determined by a pathologist. |
| Secondary | Tumor down-staging rate | up to 8 weeks after surgery | Tumor down-staging is defined as any stage reduction between clinical and pathologic stage |
| Secondary | Major pathological response (MPR) rate | up to 8 weeks after surgery | Major pathological response (MPR) rate is defined as the proportion of participants whose percentage of residual tumor in the stomach and lymph node decreased to \< 10%, as determined by a pathologist. |
| Secondary | 3 years disease-free survival (DFS) rate | up to 4 years | 3 years disease-free survival (DFS) rate is defined as proportion of participants who have no recurrence or metastasis after 3 years of radical treatment |
| Secondary | 5 years overall survival (OS) rate | up to 6 years | 5 years overall survival (OS) rate is defined as proportion of participants who survived 5 years after radical treatment |
| Secondary | Adverse event | up to 30 days after last treatment administration | All grades of adverse events, all grades of treatment related adverse events, serious of adverse events |
| Secondary | Overall response rate ( ORR) | up to 30 days after last preoperative treatment administration | Overall response rate ( ORR) is defined as proportion of participants who have a best response of CR or PR |
| Secondary | Disease Control Rate (DCR) | up to 30 days after last preoperative treatment administration | Disease Control Rate (DCR) is defined as proportion of participants who have a best response of CR、PR or SD |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04982939
GET https://conductscience.org/api/trials/v1/NCT04982939/registered